Global Enzyme Replacement Therapy

Enzyme Replacement Therapy Comprehensive Study by Application (Gaucher Disease, Fabry Disease, MPS Disease, Gastrointestinal Disease, Others), Enzyme (Imiglucerase, Agalsidase Beta, Taliglucerase, Velaglucerase Alfa, Laronidase, Alglucosidase Alfa, Others), Route of Administration (Injectable Agents, Oral Agents), Distribution Channel (Hospital Pharmacies, Specialty Treatment Pharmacies, Retail Pharmacies) Players and Region - Global Market Outlook to 2030

Enzyme Replacement Therapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Enzyme Replacement Therapy
A rare disease is defined as a disease that affects a small percentage of the general population. Drugs used for the treatment of rare diseases are called orphan drugs. Enzyme Replacement Therapy (ERT) is the treatment for rare diseases. According Global genes.org, 80% of rare diseases are of genetic origin. There are approximately 7,000 different types of rare diseases. Approximately 50% of the people affected by rare diseases are children. According to the Kakkis Every life Foundations, FDA-approved drugs are not available for 95% of rare diseases. ERT replaces an enzyme that is absent in the body. ERT is available for diseases such as fabry disease, gaucher disease, mucopolysaccharidosis, Pompe disease, and lysosomal acid lipase deficiency, among others.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Enzyme Replacement Therapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Johnson & Johnson (United States), Sanofi (France), Shire (United States), BioMarin (United States), AbbVie (United States), Alexion (United States), Allergan (Ireland), Horizon Pharma (Dublin), Actelion (Switzerland) and Recordati Rare Diseases (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Digestive Care and Leadiant Biosciences.

Segmentation Overview
AMA Research has segmented the market of Global Enzyme Replacement Therapy market by , Application (Gaucher Disease, Fabry Disease, MPS Disease, Gastrointestinal Disease and Others) and Region.



On the basis of geography, the market of Enzyme Replacement Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Enzyme , the sub-segment i.e. Imiglucerase will boost the Enzyme Replacement Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Injectable Agents will boost the Enzyme Replacement Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Enzyme Replacement Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancement in the medical sector

Market Growth Drivers:
Increase in healthcare expenditure and prevalence of rare diseases and Growth in the demand for ERT to improve the treatment of rare diseases

Challenges:
lack of regulatory framework

Restraints:
Availability of alternative treatment options and Dearth of skilled healthcare professionals

Opportunities:
Increase in government spending on healthcare infrastructure, such as favorable reimbursement for ERT

Market Leaders and their expansionary development strategies
In November 2020, Retrophin, Inc. announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). OT-58 is a novel investigational human enzyme replacement therapy being evaluated in Phase 1/2 development for the treatment of classical HCU, a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to life-threatening thrombotic events such as stroke and heart attacks, ophthalmologic and skeletal complications, as well as developmental delay.
In November 2023, Takeda launched Adzynma (ADAMTS13, recombinant-krhn) to treat adults and children with congenital thrombotic thrombocytopenic purpura (cTTP). The FDA granted approval to Adzynma in early November 2023 as a prophylactic or on-demand enzyme replacement therapy.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Enzyme Replacement Therapy Provider, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Gaucher Disease
  • Fabry Disease
  • MPS Disease
  • Gastrointestinal Disease
  • Others
By Enzyme
  • Imiglucerase
  • Agalsidase Beta
  • Taliglucerase
  • Velaglucerase Alfa
  • Laronidase
  • Alglucosidase Alfa
  • Others

By Route of Administration
  • Injectable Agents
  • Oral Agents

By Distribution Channel
  • Hospital Pharmacies
  • Specialty Treatment Pharmacies
  • Retail Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in healthcare expenditure and prevalence of rare diseases
      • 3.2.2. Growth in the demand for ERT to improve the treatment of rare diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of regulatory framework
    • 3.4. Market Trends
      • 3.4.1. Advancement in the medical sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Enzyme Replacement Therapy, by Application, Enzyme , Route of Administration, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Enzyme Replacement Therapy (Value)
      • 5.2.1. Global Enzyme Replacement Therapy by: Application (Value)
        • 5.2.1.1. Gaucher Disease
        • 5.2.1.2. Fabry Disease
        • 5.2.1.3. MPS Disease
        • 5.2.1.4. Gastrointestinal Disease
        • 5.2.1.5. Others
      • 5.2.2. Global Enzyme Replacement Therapy by: Route of Administration (Value)
        • 5.2.2.1. Injectable Agents
        • 5.2.2.2. Oral Agents
      • 5.2.3. Global Enzyme Replacement Therapy by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Specialty Treatment Pharmacies
        • 5.2.3.3. Retail Pharmacies
      • 5.2.4. Global Enzyme Replacement Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Enzyme Replacement Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Shire (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BioMarin (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alexion (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergan (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Horizon Pharma (Dublin)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Actelion (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Recordati Rare Diseases (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Enzyme Replacement Therapy Sale, by Application, Enzyme , Route of Administration, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Enzyme Replacement Therapy (Value)
      • 7.2.1. Global Enzyme Replacement Therapy by: Application (Value)
        • 7.2.1.1. Gaucher Disease
        • 7.2.1.2. Fabry Disease
        • 7.2.1.3. MPS Disease
        • 7.2.1.4. Gastrointestinal Disease
        • 7.2.1.5. Others
      • 7.2.2. Global Enzyme Replacement Therapy by: Route of Administration (Value)
        • 7.2.2.1. Injectable Agents
        • 7.2.2.2. Oral Agents
      • 7.2.3. Global Enzyme Replacement Therapy by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Specialty Treatment Pharmacies
        • 7.2.3.3. Retail Pharmacies
      • 7.2.4. Global Enzyme Replacement Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Enzyme Replacement Therapy: by Application(USD Million)
  • Table 2. Enzyme Replacement Therapy Gaucher Disease , by Region USD Million (2018-2023)
  • Table 3. Enzyme Replacement Therapy Fabry Disease , by Region USD Million (2018-2023)
  • Table 4. Enzyme Replacement Therapy MPS Disease , by Region USD Million (2018-2023)
  • Table 5. Enzyme Replacement Therapy Gastrointestinal Disease , by Region USD Million (2018-2023)
  • Table 6. Enzyme Replacement Therapy Others , by Region USD Million (2018-2023)
  • Table 7. Enzyme Replacement Therapy: by Route of Administration(USD Million)
  • Table 8. Enzyme Replacement Therapy Injectable Agents , by Region USD Million (2018-2023)
  • Table 9. Enzyme Replacement Therapy Oral Agents , by Region USD Million (2018-2023)
  • Table 10. Enzyme Replacement Therapy: by Distribution Channel(USD Million)
  • Table 11. Enzyme Replacement Therapy Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Enzyme Replacement Therapy Specialty Treatment Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Enzyme Replacement Therapy Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 14. South America Enzyme Replacement Therapy, by Country USD Million (2018-2023)
  • Table 15. South America Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 16. South America Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 17. South America Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 18. South America Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 19. Brazil Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 20. Brazil Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 21. Brazil Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 22. Brazil Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 23. Argentina Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 24. Argentina Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 25. Argentina Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 26. Argentina Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 27. Rest of South America Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 29. Rest of South America Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 30. Rest of South America Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 31. Asia Pacific Enzyme Replacement Therapy, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 34. Asia Pacific Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 35. Asia Pacific Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 36. China Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 37. China Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 38. China Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 39. China Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 40. Japan Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 41. Japan Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 42. Japan Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 43. Japan Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 44. India Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 45. India Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 46. India Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 47. India Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 48. South Korea Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 49. South Korea Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 50. South Korea Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 51. South Korea Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 52. Taiwan Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 53. Taiwan Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 54. Taiwan Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 55. Taiwan Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 56. Australia Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 57. Australia Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 58. Australia Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 59. Australia Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 64. Europe Enzyme Replacement Therapy, by Country USD Million (2018-2023)
  • Table 65. Europe Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 66. Europe Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 67. Europe Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 68. Europe Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 69. Germany Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 70. Germany Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 71. Germany Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 72. Germany Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 73. France Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 74. France Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 75. France Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 76. France Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 77. Italy Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 78. Italy Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 79. Italy Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 80. Italy Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 81. United Kingdom Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 82. United Kingdom Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 83. United Kingdom Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 84. United Kingdom Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 85. Netherlands Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 86. Netherlands Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 87. Netherlands Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 88. Netherlands Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 89. Rest of Europe Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 90. Rest of Europe Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 91. Rest of Europe Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 92. Rest of Europe Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 93. MEA Enzyme Replacement Therapy, by Country USD Million (2018-2023)
  • Table 94. MEA Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 95. MEA Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 96. MEA Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 97. MEA Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 98. Middle East Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 99. Middle East Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 100. Middle East Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 101. Middle East Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 102. Africa Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 103. Africa Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 104. Africa Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 105. Africa Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 106. North America Enzyme Replacement Therapy, by Country USD Million (2018-2023)
  • Table 107. North America Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 108. North America Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 109. North America Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 110. North America Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 111. United States Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 112. United States Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 113. United States Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 114. United States Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 115. Canada Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 116. Canada Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 117. Canada Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 118. Canada Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 119. Mexico Enzyme Replacement Therapy, by Application USD Million (2018-2023)
  • Table 120. Mexico Enzyme Replacement Therapy, by Enzyme USD Million (2018-2023)
  • Table 121. Mexico Enzyme Replacement Therapy, by Route of Administration USD Million (2018-2023)
  • Table 122. Mexico Enzyme Replacement Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Enzyme Replacement Therapy: by Application(USD Million)
  • Table 134. Enzyme Replacement Therapy Gaucher Disease , by Region USD Million (2025-2030)
  • Table 135. Enzyme Replacement Therapy Fabry Disease , by Region USD Million (2025-2030)
  • Table 136. Enzyme Replacement Therapy MPS Disease , by Region USD Million (2025-2030)
  • Table 137. Enzyme Replacement Therapy Gastrointestinal Disease , by Region USD Million (2025-2030)
  • Table 138. Enzyme Replacement Therapy Others , by Region USD Million (2025-2030)
  • Table 139. Enzyme Replacement Therapy: by Route of Administration(USD Million)
  • Table 140. Enzyme Replacement Therapy Injectable Agents , by Region USD Million (2025-2030)
  • Table 141. Enzyme Replacement Therapy Oral Agents , by Region USD Million (2025-2030)
  • Table 142. Enzyme Replacement Therapy: by Distribution Channel(USD Million)
  • Table 143. Enzyme Replacement Therapy Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 144. Enzyme Replacement Therapy Specialty Treatment Pharmacies , by Region USD Million (2025-2030)
  • Table 145. Enzyme Replacement Therapy Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 146. South America Enzyme Replacement Therapy, by Country USD Million (2025-2030)
  • Table 147. South America Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 148. South America Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 149. South America Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 150. South America Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 151. Brazil Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 152. Brazil Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 153. Brazil Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 154. Brazil Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 155. Argentina Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 156. Argentina Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 157. Argentina Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 158. Argentina Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 159. Rest of South America Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 160. Rest of South America Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 161. Rest of South America Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 162. Rest of South America Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 163. Asia Pacific Enzyme Replacement Therapy, by Country USD Million (2025-2030)
  • Table 164. Asia Pacific Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 165. Asia Pacific Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 166. Asia Pacific Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 167. Asia Pacific Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 168. China Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 169. China Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 170. China Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 171. China Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 172. Japan Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 173. Japan Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 174. Japan Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 175. Japan Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 176. India Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 177. India Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 178. India Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 179. India Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 180. South Korea Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 181. South Korea Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 182. South Korea Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 183. South Korea Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 184. Taiwan Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 185. Taiwan Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 186. Taiwan Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 187. Taiwan Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 188. Australia Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 189. Australia Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 190. Australia Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 191. Australia Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 196. Europe Enzyme Replacement Therapy, by Country USD Million (2025-2030)
  • Table 197. Europe Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 198. Europe Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 199. Europe Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 200. Europe Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 201. Germany Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 202. Germany Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 203. Germany Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 204. Germany Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 205. France Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 206. France Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 207. France Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 208. France Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 209. Italy Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 210. Italy Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 211. Italy Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 212. Italy Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 213. United Kingdom Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 214. United Kingdom Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 215. United Kingdom Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 216. United Kingdom Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 217. Netherlands Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 218. Netherlands Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 219. Netherlands Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 220. Netherlands Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 221. Rest of Europe Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 222. Rest of Europe Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 223. Rest of Europe Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 224. Rest of Europe Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 225. MEA Enzyme Replacement Therapy, by Country USD Million (2025-2030)
  • Table 226. MEA Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 227. MEA Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 228. MEA Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 229. MEA Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 230. Middle East Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 231. Middle East Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 232. Middle East Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 233. Middle East Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 234. Africa Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 235. Africa Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 236. Africa Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 237. Africa Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 238. North America Enzyme Replacement Therapy, by Country USD Million (2025-2030)
  • Table 239. North America Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 240. North America Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 241. North America Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 242. North America Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 243. United States Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 244. United States Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 245. United States Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 246. United States Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 247. Canada Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 248. Canada Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 249. Canada Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 250. Canada Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 251. Mexico Enzyme Replacement Therapy, by Application USD Million (2025-2030)
  • Table 252. Mexico Enzyme Replacement Therapy, by Enzyme USD Million (2025-2030)
  • Table 253. Mexico Enzyme Replacement Therapy, by Route of Administration USD Million (2025-2030)
  • Table 254. Mexico Enzyme Replacement Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Enzyme Replacement Therapy: by Application USD Million (2018-2023)
  • Figure 5. Global Enzyme Replacement Therapy: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Enzyme Replacement Therapy: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Enzyme Replacement Therapy Share (%), by Country
  • Figure 8. Asia Pacific Enzyme Replacement Therapy Share (%), by Country
  • Figure 9. Europe Enzyme Replacement Therapy Share (%), by Country
  • Figure 10. MEA Enzyme Replacement Therapy Share (%), by Country
  • Figure 11. North America Enzyme Replacement Therapy Share (%), by Country
  • Figure 12. Global Enzyme Replacement Therapy share by Players 2023 (%)
  • Figure 13. Global Enzyme Replacement Therapy share by Players (Top 3) 2023(%)
  • Figure 14. Global Enzyme Replacement Therapy share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 17. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 18. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 19. Sanofi (France) Revenue: by Geography 2023
  • Figure 20. Shire (United States) Revenue, Net Income and Gross profit
  • Figure 21. Shire (United States) Revenue: by Geography 2023
  • Figure 22. BioMarin (United States) Revenue, Net Income and Gross profit
  • Figure 23. BioMarin (United States) Revenue: by Geography 2023
  • Figure 24. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 25. AbbVie (United States) Revenue: by Geography 2023
  • Figure 26. Alexion (United States) Revenue, Net Income and Gross profit
  • Figure 27. Alexion (United States) Revenue: by Geography 2023
  • Figure 28. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Allergan (Ireland) Revenue: by Geography 2023
  • Figure 30. Horizon Pharma (Dublin) Revenue, Net Income and Gross profit
  • Figure 31. Horizon Pharma (Dublin) Revenue: by Geography 2023
  • Figure 32. Actelion (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Actelion (Switzerland) Revenue: by Geography 2023
  • Figure 34. Recordati Rare Diseases (United States) Revenue, Net Income and Gross profit
  • Figure 35. Recordati Rare Diseases (United States) Revenue: by Geography 2023
  • Figure 36. Global Enzyme Replacement Therapy: by Application USD Million (2025-2030)
  • Figure 37. Global Enzyme Replacement Therapy: by Route of Administration USD Million (2025-2030)
  • Figure 38. Global Enzyme Replacement Therapy: by Distribution Channel USD Million (2025-2030)
  • Figure 39. South America Enzyme Replacement Therapy Share (%), by Country
  • Figure 40. Asia Pacific Enzyme Replacement Therapy Share (%), by Country
  • Figure 41. Europe Enzyme Replacement Therapy Share (%), by Country
  • Figure 42. MEA Enzyme Replacement Therapy Share (%), by Country
  • Figure 43. North America Enzyme Replacement Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson (United States)
  • Sanofi (France)
  • Shire (United States)
  • BioMarin (United States)
  • AbbVie (United States)
  • Alexion (United States)
  • Allergan (Ireland)
  • Horizon Pharma (Dublin)
  • Actelion (Switzerland)
  • Recordati Rare Diseases (United States)
Additional players considered in the study are as follows:
Digestive Care , Leadiant Biosciences
Select User Access Type

Key Highlights of Report


Jan 2024 218 Pages 69 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Enzyme Replacement Therapy Quantitative research analysis
Global Enzyme Replacement Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Johnson & Johnson (United States), Sanofi (France), Shire (United States), BioMarin (United States), AbbVie (United States), Alexion (United States), Allergan (Ireland), Horizon Pharma (Dublin), Actelion (Switzerland) and Recordati Rare Diseases (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancement in the medical sector" is seen as one of major influencing trends for Enzyme Replacement Therapy Market during projected period 2023-2030.
The Enzyme Replacement Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Enzyme Replacement Therapy Report?

Have a Query? Click Here

Other Related Reports

Diabetes Drugs Comprehensive Study by Type (Injectable Drugs, Oral Drugs), Application (Type 1 Diabetes, Type 2 Diabetes, Gestational diabetes), Distribution Channel (Hospital Pharmacies, Retail Phar...
$ 3350
Weight Loss Drugs Comprehensive Study by Type (Liquid, Tablets), Application (Weight-reducing Aid, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Aspergillosis Drugs Comprehensive Study by Type (Allergic Bronchopulmonary Aspergillosis, Allergic Aspergillus Sinusitis, Invasive Aspergillosis, Cutaneous (skin) Aspergillosis, Chronic Pulmonary Asp...
$ 3750
Hydrocodone Bitartrate Comprehensive Study by Type (< 98%, > 98%), Application (Hydrocodone Bitartrate Capsule, Hydrocodone Bitartrate Extended-Release Tablets, Hydrocodone Bitartrate Oral Solutions)...
$ 3650
Ankle Splints Comprehensive Study by Type (Air-Stirrup Ankle Brace, Other), Application (High Ankle Sprains, Sub-acute Ankle Sprains, Chronic Ankle Sprains), Distribution Channel (Orthopedic Clinics,...
$ 3650
Omega 3 Comprehensive Study by Type (ALA (Alpha-Linolenic Acid), DHA (Docosahexaenoic Acid), EPA (Eicosapentaenoic Acid)), Application (Dietary Supplement, Pharmaceutical, Infant Formula, Food & Beve...
$ 3750